Journal of Clinical Oncology
Articles in this Issue
Accuracy and inclusiveness of health insurance information in generative artificial intelligence.
e13723 Background: GenerativeAI (genAI) has the potential to revolutionize how cancer patients seek information. As more cancer survivors look to genAI fo...
Project Optimus: Principles, challenges, and a paradigm shift in dose optimization for cancer therapies.
e23019 Background: Traditional phase 1 trial designs for cytotoxic agents assume that both clinical benefit and toxicity increase with higher doses, aimin...
A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma.
TPS9600 Background: IL-12 stimulates innate and adaptive tumor immunity. Tolododekin alfa (ANK-101) is an anchored drug conjugate that creates a strong li...
Geriatric assessment and management with a question prompt list using a web-based application to reduce treatment toxicity in older patients with cancer: A randomized controlled trial (J-SUPPORT 2101 study).
1505 Background: Older adults with cancer experience aging-related physical, psychosocial and cognitive challenges that require comprehensive communicatio...
Racial disparities in oncology clinical trials by absolute neutrophil count eligibility criteria: A single center retrospective analysis.
1583 Background: Black individuals have been historically underrepresented in clinical trials. The Duffy-null phenotype leads to clinically insignificant...
Correlation of [ <sup>68</sup> Ga]Ga-PSMA-11 PET biodistribution with immunohistochemical PSMA expression in hepatocellular carcinoma: Results from the prospective study MORE-PSMA.
e16326 Background: Hepatocellular carcinoma (HCC) is challenging to diagnose beyond CT and MRI. Prostate-specific membrane antigen (PSMA), a known marker...
Breast amyloidosis: A systematic review.
e19572 Background: Breast amyloidosis is a rare occurrence often initially mistaken as malignancy on screening mammogram. It has only been reported in cas...
The HALP score as a prognostic biomarker in non-small cell lung cancer: A comprehensive meta-analysis of over 7,000 patients.
e20031 Background: The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score is an emerging prognostic biomarker in oncology, reflecting nutritional,...
Structural classification of <i>FOXA1</i> alterations and their association with clinical outcomes and transcriptional profiles in prostate cancer patients.
e17071 Background: FOXA1 alterations occur in 10-15% of prostate cancers; however, due to variability in mutational mechanism, clinical outcom...
A phase II trial of neoadjuvant chemotherapy combined with anti-angiogenesis therapy and immunotherapy for resectable stageII-IIIB esophageal squamous cell carcinoma.
e16124 Background: It has been proven that neoadjuvant therapy plays a vital part in the therapy of resectable esophageal squamous cell carcinoma (ESCC)....
ARC101-P1-101: A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors.
TPS2671 Background: T-cell Engagers (TCEs) are emerging as a promising immuno-therapeutic modality in the treatment of solid tumors, demonstrating outstan...
Impact of alcohol dependence on the efficacy of immune checkpoint inhibitors: A comprehensive real-world retrospective cohort analysis.
e23091 Background: Immune checkpoint inhibitors (ICIs) are pivotal in treating various cancers by targeting PD-1 and PD-L1. Alcohol consumption has been a...
National trends in prevalence of pancreatic cancer in adults aged 70 and older: A global burden of disease analysis (1990–2021).
e16418 Background: Pancreatic cancer remains one of the most fatal malignancies globally, posing a significant burden on older populations. Despite numero...
Distinct microenvironment phenotypes across tumor, vascular, and immune compartments from ramucirumab plus pembrolizumab in refractory gastric cancer: A phase II trial.
4034 Background: Combining immune checkpoint inhibitor (ICI) with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising...
Racial disparities in hospital outcomes for uterine and ovarian cancer patients: A National Inpatient Sample database (NIS) analysis.
e17645 Background: Racial disparities in healthcare outcomes are well-reported in different medical conditions. In this study, we aimed to explore the rac...
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAF <sup>V600E</sup> -mutated metastatic non-small cell lung cancer: The FRONT-BRAF study.
8574 Background: Patients (pts) with BRAF V600E mutated non-small cell lung cancer (NSCLC) can be effectively treated with BRAF an...
Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker based study (Alliance A032102).
TPS5114 Background: Advances in genomic sequencing have allowed for a deeper understanding of the molecular complexity of metastatic castration-resistant...
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors: Results on safety, pharmacokinetics, and anti-tumor activity.
3124 Background: Zavondemstat is an epigenetic targeting inhibitor of KDM4 histone demethylase. Dysregulation of KDM4 enzymes (isoforms A-D) has been impl...
A phase II study of pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma: ECOG-ACRIN EA2187.
4115 Background: Cholangiocarcinoma is a rare and aggressive malignancy with limited therapeutic options, particularly in advanced stages. Resistance to f...
A post discharge palliative care pilot clinic for cancer patients.
e24056 Background: Palliative care is an important intervention in helping alleviate symptom burden and decreasing suffering in patients facing serious il...
Nasopharyngeal carcinoma outcomes in a predominantly African American population: A single-center experience.
e18020 Background: Nasopharyngeal carcinoma (NPC) is an aggressive and unique subtype of head and neck cancer, largely associated with Epstein-Barr virus...
From retrospective analysis to real-world impact: Mismatch repair deficiency detection in gliomas by tissue and liquid ctDNA NGS in glioma management.
2070 Background: Tissue biopsy remains the gold standard for Microsatellite Instability and MMR (mismatch repair) gene alteration assessment. The regulato...
Impact of rurality on patients with synchronous colorectal cancers.
e23297 Background: Nearly 20% of Americans reside in rural communities, defined by the U.S. Census as areas not included within urbanized regions or clust...
Sequential versus concurrent strategy of immunotherapy and radiotherapy in advanced non-small-cell lung cancer: A territory-wide multicenter study (OCEANUS study).
8073 Background: Combination of immunotherapy with radiotherapy (iRT) has been a hot topic of research during last 10+ years with controversial results. I...
Lactylation-mediated IGF2BPs/rmrp axis and effects on bladder cancer progression through the regulation of cancer cells and cancer-associated fibroblasts.
e16576 Background: Bladder cancer (BCa) is a common malignancy with high incidence and mortality. Epigenetic modifications, particularly N6-methyladenosin...